A trial of Rigosertib for Pediatric RASopathies
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2018
Price : $35 *
At a glance
- Drugs Rigosertib (Primary)
- Indications Developmental disabilities
- Focus Therapeutic Use
- 13 Nov 2018 According to an Onconova Therapeutics media release, a clinical trial protocol concept has been developed and is under review. Based on NCI guidance, the Company expects the first patient to be treated in the first half of 2019.
- 16 Nov 2017 New trial record
- 09 Nov 2017 This trial is expected to start next year at National Cancer Institute and will be funded by the NIH, as reported in an Onconova Therapeutics media release.